Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $1.75, in-line with the analyst estimate of $1.75. Revenue for the quarter came in at $1.91 billion versus the consensus estimate of $1.95 billion.
“Once again, we grew revenues and delivered strong earningsgrowth in the second quarter,\” said Steve Rusckowski, Chairman, President and CEO. “We continue to strengthen our strategic relationship with UnitedHealth Group and are excited to serve as a national in-network lab provider for UnitedHealthcare members beginning January 1, 2019. Overall, we remain focused on delivering on our two-point strategy and have updated our outlook for the full-year 2018 to reflect our confidence in achieving our commitments for the year.”
GUIDANCE:
Quest Diagnostics sees FY2018 EPS of $6.53-$6.67, versus the consensus of $6.61. Quest Diagnostics sees FY2018 revenue of $7.7-7.74 billion, versus the consensus of $7.72 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.